拨康视云™
Cloudbreak Pharma

CLOUDBREAK PHARMA INC.
撥康視雲製藥有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2592)

POSTPONEMENT OF THE ANNUAL GENERAL MEETING

Reference is made to the annual report for the year ended 31 December 2025 (the "**Annual Report**") published by Cloudbreak Pharma Inc. (the "**Company**") on 31 March 2026, in relation to among other things, the date of the forthcoming annual general meeting of the Company (the "**Annual General Meeting**"). Unless otherwise indicated, the terms used in this announcement shall have the same meaning as defined in the Annual Report.

Pursuant to the Annual Report, the Annual General Meeting is originally scheduled to be held on Friday, 29 May 2026. The Board hereby announces that as additional time is required to prepare for the Annual General Meeting, the Annual General Meeting will be postponed to Friday, 26 June 2026.

Save as disclosed above, all other information and content contained in the Annual Report remain unchanged.

By order of the Board
Cloudbreak Pharma Inc.
Dr. NI, Jinsong
Chairman, Executive Director and Chief Executive Officer

Hong Kong, 20 May 2026

As at the date of this announcement, the Board comprises: (i) Dr. Ni Jinsong, Mr. Dinh Son Van and Dr. Yang Rong as executive Directors; (ii) Dr. Li Jun Zhi, Mr. Cao Xu and Mr. Xia Zhidong as non-executive Directors; and (iii) Ms. Nie Sijiang, Mr. Ma Yiu Ho Peter and Mr. Lee Alex Jao Jang as independent non-executive Directors.

* *For identification purpose only*